2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]
Oral gonorrhea antibiotic Nuzolvence approved just weeks ago The Food and Drug Administration recently approved Nuzolvence (zoliflodacin) as a first‑in‑class ...